Agenus Inc (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies, announced yesterday that it has appointed I-O drug development experts to key leadership positions.
These appointments are intended to help advance multiple clinical programs and planned BLA filings by 2020.
The company has named Dr Sunil Gupta as its vice president of regulatory and pharmacovigilance. He is a trained oncologist with around 30 years in senior leadership positions in clinical development and regulatory affairs. He joins Agenus from Sanofi where he had a career for 22 years including leading the approvals of Cemiplimab (anti-PD-1), Iniparib (PARP inhibition), Oxaliplatin and Taxotere.
The firm has also appointed Dr Anna Wijatyk as its vice president of clinical development. She was earlier vice president oncology & global development lead in hematologic cancers at Shire. She is a clinician with more than 20 years of experience in leadership positions at Bristol-Myers Squibb, Baxter, and Shire in oncology and rare diseases, leading to approvals of products with the FDA, EMA and Health Canada.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval